Reversal of acute and chronic synovial inflammation by anti- transforming growth factor beta

doi:10.1084/jem.177.1.225

This Article

	Full Text (PDF)
	Alert me when this article is cited
	Citation Map

Services

	Email this article
	Similar articles in this journal
	Similar articles in PubMed
	Alert me to new content in the JEM
	Download to citation manager

Citing Articles

	Citing Articles via HighWire
	Citing Articles via CrossRef
	Citing Articles via Google Scholar

Google Scholar

	Articles by Wahl, S. M.
	Articles by Dasch, J. R.
	Search for Related Content

PubMed

	PubMed Citation
	Articles by Wahl, S. M.
	Articles by Dasch, J. R.


Social Bookmarking

	What's this?

ARTICLES

Reversal of acute and chronic synovial inflammation by anti- transforming growth factor beta

SM Wahl, JB Allen, GL Costa, HL Wong and JR Dasch
Laboratory of Immunology, Cellular Immunology Section, National Institute of Dental Research, National Institutes of Health, Bethesda, Maryland 20892.

Transforming growth factor beta (TGF-beta) induces leukocyte recruitment and activation, events central to an inflammatory response. In this study, we demonstrate that antagonism of TGF-beta with a neutralizing antibody not only blocks inflammatory cell accumulation, but also tissue pathology in an experimental model of chronic erosive polyarthritis. Intraarticular injection of monoclonal antibody 1D11.16, which inhibits both TGF-beta 1 and TGF-beta 2 bioactivity, into animals receiving an arthropathic dose of bacterial cell walls significantly inhibits arthritis. Inhibition was observed with a single injection of 50 micrograms antibody, and a 1-mg injection blocked acute inflammation > 75% compared with the contralateral joints injected with an irrelevant isotype control antibody (MOPC21) as quantitated by an articular index (AI = 0.93 +/- 0.23 for 1D11.16, and AI = 4.0 +/- 0 on day 4; p < 0.001). Moreover, suppression of the acute arthritis achieved with a single injection of antibody was sustained into the chronic, destructive phase of the disease (on day 18, AI = 0.93 +/- 0.07 vs. AI = 2.6 +/- 0.5; p < 0.01). The decreased inflammatory index associated with anti-TGF-beta treatment was consistent with histopathologic and radiologic evidence of a therapeutic response. These data implicate TGF-beta as a profound agonist not only in the early events responsible for synovial inflammation, but also in the chronicity of streptococcal cell wall fragment-induced inflammation culminating in destructive pathology. Interrupting the cycle of leukocyte recruitment and activation with TGF-beta antagonists may provide a mechanism for resolution of chronic destructive lesions.
Add to CiteULike CiteULike Add to Complore Complore Add to Connotea Connotea Add to Del.icio.us Del.icio.us Add to Digg Digg Add to Reddit Reddit Add to Technorati Technorati What's this?

This article has been cited by other articles:

Sakuma, M., Hatsushika, K., Koyama, K., Katoh, R., Ando, T., Watanabe, Y., Wako, M., Kanzaki, M., Takano, S., Sugiyama, H., Hamada, Y., Ogawa, H., Okumura, K., Nakao, A. (2007). TGF-{beta} type I receptor kinase inhibitor down-regulates rheumatoid synoviocytes and prevents the arthritis induced by type II collagen antibody. Int Immunol 19: 117-126 [Abstract] [Full Text]
Murano, M., Xiong, X., Murano, N., Salzer, J. L., Lafaille, J. J., Tsiagbe, V. K. (2006). Latent TGF-{beta}1-transduced CD4+ T cells suppress the progression of allergic encephalomyelitis. J. Leukoc. Biol. 79: 140-146 [Abstract] [Full Text]
Sasse, S. A., Jadus, M. R., Kukes, G. D. (2003). Pleural Fluid Transforming Growth Factor-{beta}1 Correlates with Pleural Fibrosis in Experimental Empyema. Am. J. Respir. Crit. Care Med. 168: 700-705 [Abstract] [Full Text]
Myers, L., Takahashi, C., Mittler, R. S., Rossi, R. J., Vella, A. T. (2003). Effector CD8 T cells possess suppressor function after 4-1BB and Toll-like receptor triggering. Proc. Natl. Acad. Sci. USA 100: 5348-5353 [Abstract] [Full Text]
Tanaka, M., Ozaki, S., Kawabata, D., Kishimura, M., Osakada, F., Okubo, M., Murakami, M., Nakao, K., Mimori, T. (2003). Potential preventive effects of follistatin-related protein/TSC-36 on joint destruction and antagonistic modulation of its autoantibodies in rheumatoid arthritis. Int Immunol 15: 71-77 [Abstract] [Full Text]
Zhang, Y., McCormick, L. L., Desai, S. R., Wu, C., Gilliam, A. C. (2002). Murine Sclerodermatous Graft-Versus-Host Disease, a Model for Human Scleroderma: Cutaneous Cytokines, Chemokines, and Immune Cell Activation. J. Immunol. 168: 3088-3098 [Abstract] [Full Text]
Braley-Mullen, H., Chen, K., Wei, Y., Yu, S. (2001). Role of TGF{beta} in Development of Spontaneous Autoimmune Thyroiditis in NOD.H-2h4 Mice. J. Immunol. 167: 7111-7118 [Abstract] [Full Text]
Chen, K., Wei, Y., Sharp, G. C., Braley-Mullen, H. (2000). Characterization of thyroid fibrosis in a murine model of granulomatous experimental autoimmune thyroiditis. J. Leukoc. Biol. 68: 828-835 [Abstract] [Full Text]
McCormick, L. L., Zhang, Y., Tootell, E., Gilliam, A. C. (1999). Anti-TGF-{beta} Treatment Prevents Skin and Lung Fibrosis in Murine Sclerodermatous Graft-Versus-Host Disease: A Model for Human Scleroderma. J. Immunol. 163: 5693-5699 [Abstract] [Full Text]
van Tol, E. A. F., Holt, L., Li, F. L., Kong, F.-M., Rippe, R., Yamauchi, M., Pucilowska, J., Lund, P. K., Sartor, R. B. (1999). Bacterial cell wall polymers promote intestinal fibrosis by direct stimulation of myofibroblasts. Am. J. Physiol. Gastrointest. Liver Physiol. 277: G245-G255 [Abstract] [Full Text]
Li, J., Hunter, C. A., Farrell, J. P. (1999). Anti-TGF-{beta} Treatment Promotes Rapid Healing of Leishmania major Infection in Mice by Enhancing In Vivo Nitric Oxide Production. J. Immunol. 162: 974-979 [Abstract] [Full Text]
Chen, W., Jin, W., Cook, M., Weiner, H. L., Wahl, S. M. (1998). Oral Delivery of Group A Streptococcal Cell Walls Augments Circulating TGF-{beta} and Suppresses Streptococcal Cell Wall Arthritis. J. Immunol. 161: 6297-6304 [Abstract] [Full Text]
Wang, J., Zheng, H., Sung, C.-C., Richter, K. K., Hauer-Jensen, M. (1998). Cellular Sources of Transforming Growth Factor-� Isoforms in Early and Chronic Radiation Enteropathy. Am. J. Pathol. 153: 1531-1540 [Abstract] [Full Text]
Chen, L. Z., Hochwald, G. M., Huang, C., Dakin, G., Tao, H., Cheng, C., Simmons, W. J., Dranoff, G., Thorbecke, G. J. (1998). Gene therapy in allergic encephalomyelitis using myelin basic protein-specific T cells engineered to express latent transforming growth factor-beta 1. Proc. Natl. Acad. Sci. USA 95: 12516-12521 [Abstract] [Full Text]
Bridoux, F., Badou, A., Saoudi, A., Bernard, I., Druet, E., Pasquier, R., Druet, P., Pelletier, L. (1997). Transforming Growth Factor beta �(TGF-beta )-dependent Inhibition of T Helper Cell 2�(Th2)-induced Autoimmunity by Self-Major Histocompatibility Complex (MHC) Class II-specific, Regulatory CD4+ T Cell Lines. J. Exp. Med. 185: 1769-1775 [Abstract] [Full Text]
Raz, E., Dudler, J., Lotz, M., Baird, S.M., Berry, C.C., Eisenberg, R.A., Carson, D.A. (1995). Modulation of disease activity in murine systemic lupus erythematosus by cytokine gene delivery. Lupus 4: 286-292 [Abstract]
Border, W. A., Noble, N. A. (1994). Transforming Growth Factor {beta} in Tissue Fibrosis. NEJM 331: 1286-1292 [Full Text]
Shah, M, Foreman, D., Ferguson, M. (1994). Neutralising antibody to TGF-beta 1,2 reduces cutaneous scarring in adult rodents. J. Cell Sci. 107: 1137-1157 [Abstract]